Vaginal Ovule
Preclinical
Vaginal Ovule is one of 5 therapeutic programs targeting Human Papilloma Virus Infection. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Human Papilloma Virus Infection
#DrugCompanyPhaseTrials
1Aldara
BBausch Health Americas, Inc.
Approved
Recombinant Human GM-CSF
EEastern Cooperative Oncology Group
Phase 2
Intron a
SanofiPreclinical
Vaginal Ovule
DDr. Lutfi Kirdar Kartal Training and Research Hospital
Preclinical
ABI-2280
AAntiva Biosciences
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Human Papilloma Virus Infection1 trial
A Randomized Controlled Trial to Evaluate the Efficacy of a Dual-Modality Immunotherapy (Oral Immunomodulator and Vaginal Ovule) for Human Papillomavirus (HPV) Clearance
Active, not recruiting·DDr. Lutfi Kirdar Kartal Training and Research Hospital·Preclinical·NCT07735039·76 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Vaginal Ovule. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]